Edition:
India

Seikagaku Corp (4548.T)

4548.T on Tokyo Stock Exchange

1,527JPY
22 Jun 2018
Change (% chg)

¥-17 (-1.10%)
Prev Close
¥1,544
Open
¥1,544
Day's High
¥1,551
Day's Low
¥1,520
Volume
160,700
Avg. Vol
170,784
52-wk High
¥2,236
52-wk Low
¥1,508

Chart for

About

SEIKAGAKU CORPORATION is principally engaged in the research, development, purchase, manufacture and sale of pharmaceutical products and limulus amebocyte lysate (LAL). The Company operates in two business segments. The Pharmaceutical business segment provides hyaluronan-based medicines for joint function improvement, ophthalmic... (more)
No analyst recommendations are available for .

Overall

Beta: 0.70
Market Cap(Mil.): ¥114,025.90
Shares Outstanding(Mil.): 56.81
Dividend: 13.00
Yield (%): 1.30

Financials

  4548.T Industry Sector
P/E (TTM): 46.89 30.95 32.74
EPS (TTM): 42.80 -- --
ROI: 3.33 14.84 14.38
ROE: 3.48 16.34 16.08

BRIEF-Seikagaku announces new drug application approval of hernicore® 1.25 units for intradiscal injection in Japan

* Says it announced that the Japanese Ministry of Health, Labour and Welfare has approved the new drug application of HERNICORE® 1.25 units for intradiscal injection in Japan, indicated for the treatment of lumbar disc herniation

23 Mar 2018

BRIEF-Seikagaku initiates a phase III clinical trial (additional study) in the U.S. for SI-6603

* Says it will initiate a Phase III clinical trial (additional study) in the U.S. for SI-6603, indicated for the treatment of radicular leg pain (i.e. sciatica) due to a lumbar disc herniation.

19 Feb 2018

Earnings vs. Estimates